Introduction
Intravenous levetiracetam has been shown to be safe and effective in treating adults and children with convulsive and nonconvulsive status epilepticus and with acute repetitive seizures. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] In contrast to phenytoin and phenobarbital, the traditionally used anticonvulsants used in the management of SE and ARS in children, there have been no reports of cardiac arrhythmias, hypotension, tissue-extravasation reactions or respiratory depression associated with levetiracetam. 6, 8, 13 In view of the rapidly increasing literature that has described the efficacy and safety of intravenous levetiracetam in a range of clinical situations, it was considered appropriate to undertake a pilot evaluation of the use of this drug in an in-patient paediatric population. The objective of this paper is to report this evaluation.
Materials and methods
Approval for the use of intravenous levetiracetam (LEV) was obtained from this institution's Clinical Development and Evaluation Group (CDEG) and the study was registered with the institution's Audit Department (number: 3405). Data were recorded on a standardised proforma with information retrieved from the medical case notes and pharmacy records. Data collection was mainly retrospective.
Acute repeated seizures (ARS) were defined as repeated myoclonic, clonic, tonic or tonic-clonic seizures (each seizure lasting less than five minutes with recovery of consciousness between each seizure) that had persisted for at least 30 min irrespective of whether they had been treated with any emergency medication (a benzodiazepine alone or a benzodiazepine with either phenytoin or phenobarbital). Convulsive status epilepticus was defined as any single and prolonged tonic-clonic seizure that had persisted for over five minutes and irrespective of whether the child had received any emergency medication. The decision to use levetiracetam as first or second-line therapy in either ARS or CSE was determined by the attending clinician. Non-convulsive status epilepticus (NCSE) was defined on the basis of both the child's clinical behaviour and electroencephalographic (EEG) activity; NCSE was not diagnosed without confirmatory EEG evidence.
Termination of the seizure was defined as successful if it stopped within 10 min of completion of the infusion and there was no recurrence within the following 24 h.
The protocol for administering intravenous levetiracetam was as followed: the initial dose was 10 mg/kg and 'rounded up' to facilitate the practical administration of the drug and infused over 10-15 min. During the final five months of the study, the dose was increased to 30 mg/kg, based on new clinical and pharmacokinetic data 8 and administered over 15 min.
All in-patients who received intravenous levetiracetam were included in the study. Patients who attended the Accident and Emergency Department (A+ED) with an acute seizure were excluded because these children are treated according to the national Advanced Paediatric Life Support (APLS) convulsive status epilepticus algorithm. Patients with established renal failure and who were on dialysis were also excluded from the study because of the reported reduced excretion of levetiracetam in this population. 14 Information was collected on the following: age and sex; seizure type; epilepsy syndrome and cause if known; the reason for the administration of intravenous levetiracetam (ARS, CSE, NCSE or for the purpose of rapidly loading the patient); other anticonvulsants used to treat the same seizure episode; loading dose of levetiracetam; response to levetiracetam and whether the child remained on the drug at final follow-up.
Results
Fifty one patients were studied between January 1st 2009 and December 31st 2010. The majority (39 [76%]) received the drug to try and terminate ARS. Four received the drug to terminate CSE and two to terminate NCSE. Details of the ages, seizure type, epilepsy syndrome and cause, occurrence of adverse effects and current follow-up of these 45 patients are shown in Tables 1-3 .
The remaining six patients received intravenous levetiracetam to replace another anti-epileptic drug because they were unable to continue with their usual maintenance AED (sodium valproate, 3 carbamazepine, 2 and lamotrigine 1 ). Three patients were undergoing a major abdominal surgical procedure and could not take oral medication, two patients had probable valproate-related bone marrow suppression and the remaining patient developed hepatic dysfunction on carbamazepine. Five of these six patients had been seizure-free for between five and 18 months when their maintenance AED was changed to intravenous levetiracetam. These patients are not included in Tables 1 and 2 . A review of pharmacy records did not identify any additional children who had received intravenous levetiracetam during the study period.
The Levetiracetam terminated the seizure in 24 of the 39 patients (62%) with ARS. Twenty of the 39 patients had received levetiracetam as the first anticonvulsant and in 13 (65%) the seizure stopped. In the remaining 19 patients, levetiracetam was given after another emergency medication and the seizure stopped in 12 (63%). Two of the 25 responders required an additional intravenous dose given within six hours of the initial dose (patients 25 and 38). Finally, an additional three patients (9, 22 and 23) became seizure-free but then relapsed after 24-36 h with no response to further doses of the anticonvulsant. Five patients showed at least a 50% reduction in seizure frequency which had been sustained at follow-up; the remaining eight patients (19.5%) showed no response.
Levetiracetam terminated three of the four (75%) patients with CSE, and the two patients with NCSE. Further seizures, but no recurrence of status occurred in two of the four patients with CSE (patients 43 and 45).
Five of the six patients who received intravenous levetiracetam to replace their usual oral anti-epileptic medication had remained seizure-free on oral levetiracetam for between seven and 14 months at final follow-up; the remaining patient, who had not been seizure-free prior to substitution with levetiracetam, showed improved seizure control after nine months. None of the six patients restarted their previous AED.
Adverse effects were observed in three children who developed aggressive behaviour, one of whom had to discontinue treatment because of persistence of this aggression (patient 4). This almost seven year-old had been described as being ''impulsive'' and ''short-tempered'' prior to receiving levetiracetam. No pre-existing behaviour problems had been reported in the two remaining patients.
Forty-two patients (82%) including 35 of the 45 patients (78%) treated for ARS or SE remained on levetiracetam at the time of final follow-up, between two and 18 months after receiving the drug.
Levetiracetam was discontinued in four patients, three because of lack of response and one because of verbal and physical aggression.
Discussion
This open, prospective study of the use of intravenous levetiracetam in a range of acute clinical situations and for different seizure types and epilepsy syndromes has shown it to be effective and associated with few side-effects. The presenting seizure, including status epilepticus, was terminated in 29 of the 45 patients (64%) with these patients remaining seizure-free at the end of follow-up. The drug was discontinued in only one patient because of an unwanted side-effect (sustained aggression). Although the initial dose of the drug increased by approximately three-fold during the course of the study, no obvious difference was subsequently observed in either the drug's efficacy or the incidence of side-effects, although the number of patients is too small to speculate on any possible dose-response.
Intravenous levetiracetam has been reported to be effective and well-tolerated and therefore clinically useful in a range of clinical situations where the administration of other long-term antiepileptic drugs might be associated with potentially severe sideeffects or clinically significant drug interactions. 15 These include:
in neonates 16 the management of acute seizures, 6-18 a severe 7 In addition, preliminary and limited randomised controlled trial data suggest that levetiracetam may be associated with fewer adverse side-effects and improved long-term outcome than phenytoin. 24 Intravenous levetiracetam was not administered in the A+ED because the current practice is that outlined in the recently revised Advanced Paediatric Life Support (APLS) guideline following the recommendation of the Status Epilepticus Working Group of the British Paediatric Neurology Association (BPNA). It is considered that any change in the acute management of children who present to the A+ED should be based on evidence from a formal randomised controlled trial (RCT).
The safety profile of any intravenously administered anticonvulsant is clearly important. Phenytoin may be associated with a number of complications including an idiosyncratic drug rash (including Stevens-Johnson syndrome), tissue extravasation leading potentially to the 'purple glove' syndrome, hypotension and cardiac arrhythmias which may be fatal. 25, 26 Finally, the drug has a problematic pharmacokinetic and pharmacodynamic profile with significant drug interactions and specifically with chemotherapeutic drugs and antibiotics. Phenobarbital may be associated with an idiosyncratic rash, sedation and significant respiratory suppression and drug interactions. Blood-monitoring is frequently required for both anticonvulsants. Finally, phenytoin must be infused over a minimum of 20-30 min, during which time the child may still be convulsing. Adverse un-wanted side effects reported with intravenous levetiracetam include headache and fatigue, which are usually transient. Aggression may also occur and may necessitate discontinuation of the drug; anecdotal evidence would suggest that children with pre-existing behaviour problems may be at greater risk. The drug had to be discontinued in only one of our 51 patients (1.9%) because of aggression; this patient had pre-existing behaviour problems manifest by impulsivity and poor angercontrol. Two other patients manifest transient aggression and irritability and neither was reported to have had any pre-existing behaviour problems. Finally, there is also no requirement to monitor blood levels of levetiracetam.
Eighty-two per cent of our patients remained on levetiracetam at final follow-up. This includes the six patients who initially received intravenous levetiracetam because they were unable to continue taking their usual oral anti-epileptic drug. This 'retention' rate is higher than the 64% of patients in whom the presenting seizure was terminated by levetiracetam and reflects the fact that the drug was both effective and well-tolerated. Finally, it is of practical importance that the drug is available in both intravenous and oral preparations, which clearly facilitates its use beyond the acute situation.
This study has a number of limitations. First, it was not a homogeneous population in terms of epilepsy syndrome or underlying cause. Second, approximately half of the patients did not receive levetiracetam as the first anticonvulsant, but only after a benzodiazepine or benzodiazepine and phenytoin/phenobarbital. However, the response rate was very similar between those who received levetiracetam as first-line treatment (65%) and those who received another long-acting anticonvulsant first (61%). Although this observation might suggest that levetiracetam is more effective when used first (65% vs. 61%), the difference could simply reflect the fact that the group who received levetiracetam after other anti-epileptic drugs was more refractory. Clearly, the numbers in the two groups are too small to make any definitive conclusion. Third, the initial loading dose changed during the study and the loading dose was considerably lower than that used in previous studies 2, [6] [7] [8] [9] 11, 13, 15 (including neonates 16 ) which have ranged from five to 50 mg/kg but most commonly in excess of 30 mg/kg. Consequently, it is of interest that our results are similar to previous studies that had employed considerably higher loading doses. Fourth, the duration of follow-up varied considerably and was under six months in 21 of the 52 patients. Fifth, it has not been possible to compare these results with any control group. Such a group would have to have used historical data on the use of other anticonvulsants used in identical clinical situations within our hospital; it is most unlikely that such a group would be identifiable. In view of the encouraging efficacy and safety profile of levetiracetam, it has been suggested that this anticonvulsant could, and perhaps should, be used earlier in the treatment of status epilepticus. 27, 28 A recently published randomised study of the initial intravenous treatment of convulsive status epilepticus in adults reported seizure cessation rates of 76.3% (levetiracetam) and 75.6% (lorazepam). 29 
Conclusion
Intravenous levetiracetam was effective and very well-tolerated in this small, heterogeneous population in the treatment of acute, repeated seizures and convulsive and non-convulsive status epilepticus. It was also effective and well-tolerated when used to replace other anti-epileptic drugs which could not be given orally. The drug potentially offers a more effective and safer option than traditional anti-epileptic drugs in treating acute, repeated (including symptomatic) seizures and status epilepticus. Growing evidence would support the view that levetiracetam should be considered as a replacement for phenytoin or phenobarbital and therefore the first-choice long-term anticonvulsant for use in the treatment of status epilepticus. This should now be confirmed (or refuted) with an RCT.
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